H.C. Wainwright Remains a Buy on Axsome Therapeutics (AXSM)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics (AXSMResearch Report), with a price target of $210.00. The company’s shares closed yesterday at $63.80.

Selvaraju covers the Healthcare sector, focusing on stocks such as Regulus, Enlivex Therapeutics, and Brainsway. According to TipRanks, Selvaraju has an average return of -31.0% and a 19.54% success rate on recommended stocks.

In addition to H.C. Wainwright, Axsome Therapeutics also received a Buy from SVB Securities’s Marc Goodman in a report issued on August 22. However, on August 30, Morgan Stanley maintained a Hold rating on Axsome Therapeutics (NASDAQ: AXSM).

See the top stocks recommended by analysts >>

The company has a one-year high of $71.98 and a one-year low of $20.63. Currently, Axsome Therapeutics has an average volume of 1.9M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Read More on AXSM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More